Key result
Copeptin plus troponin T improves AMI diagnostic accuracy over troponin T alone.
Why the study?
Does the combination of copeptin and troponin T improve the rapid rule out of acute myocardial infarction compared to troponin T alone in patients presenting to the emergency department with suggestive symptoms?
Observational (n=487)
Blinded
Does the combination of copeptin and troponin T improve the rapid rule out of acute myocardial infarction compared to troponin T alone in patients presenting to the emergency department with suggestive symptoms?
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“In the very situation of a patient presenting to the Emergency Department with symptoms suggestive of Acute Myocardial Infarction the clinician quickly needs to know whether the person is in real danger or not. Ruling out AMI in this setting is an urgent and unmet need. The use of Copeptin together with Troponin can accelerate the rule out of AMI and thus improves patient management in the ED immensely. Two thirds of these patients may be ruled out with the first blood draw and most of them probably could leave the ED very soon.”
“Following the BIC-8 interventional trial, the ESC recognizes the safety and efficacy of copeptin recommending its routine use as an additional biomarker for early rule-out of AMI in combination with troponin.”
Adding copeptin to troponin T at presentation allows for rapid and reliable rule out of acute myocardial infarction, potentially reducing the need for prolonged monitoring.
OBJECTIVES: The purpose of this study was to examine the incremental value of copeptin for rapid rule out of acute myocardial infarction (AMI). BACKGROUND: The rapid and reliable exclusion of AMI is a major unmet clinical need. Copeptin, the C-terminal part of the vasopressin prohormone, as a marker of acute endogenous stress may be useful in this setting. METHODS: In 487 consecutive patients presenting to the emergency department with symptoms suggestive of AMI, we measured levels of copeptin at presentation, using a novel sandwich immunoluminometric assay in a blinded fashion. The final diagnosis was adjudicated by 2 independent cardiologists using all available data. RESULTS: The adjudicated final diagnosis was AMI in 81 patients (17%). Copeptin levels were significantly higher in AMI patients compared with those in patients having other diagnoses (median 20.8 pmol/l vs. 6.0 pmol/l, p < 0.001). The combination of troponin T and copeptin at initial presentation resulted in an area under the receiver-operating characteristic curve of 0.97 (95% confidence interval: 0.95 to 0.98), which was significantly higher than the 0.86 (95% confidence interval: 0.80 to 0.92) for troponin T alone (p < 0.001). A copeptin level <14 pmol/l in combination with a troponin T < or =0.01 microg/l correctly ruled out AMI with a sensitivity of 98.8% and a negative predictive value of 99.7%. CONCLUSIONS: The additional use of copeptin seems to allow a rapid and reliable rule out of AMI already at presentation and may thereby obviate the need for prolonged monitoring and serial blood sampling in the majority of patients. (Advantageous Predictors of Acute Coronary Syndromes Evaluation [APACE]; NCT00470587).
No takes yet. Share an insight, caveat, or question.
Reichlin et al. (2009) conducted an observational in Acute myocardial infarction (n=487). Copeptin combined with troponin T vs. Troponin T alone was evaluated on Area under the receiver-operating characteristic curve for diagnosis of acute myocardial infarction (95% CI 0.95 to 0.98, p=<0.001). Combining copeptin and troponin T at presentation yielded a higher diagnostic accuracy for acute myocardial infarction than troponin T alone.
Synapse has enriched 10 related papers. Consider them for comparative context: